Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Name: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 — clinical trial record (NCT06565689)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study aims to provide a basis for further clinical development of YK012.

Protocol Amendment History 2 changes

notable Primary completion pushed: 2026-06-30 -> 2028-12 2026-07-19

minor Completion pushed: 2026-12-31 -> 2028-12 2026-07-19

Trial Details

NCT Number	NCT06565689
Lead Sponsor	Excyte Biopharma Ltd
Conditions	Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Enrollment	48 participants
Start Date	2023-05-09
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-17